A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

Alzheimer’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

India's federal investigating agency has alleged that Diageo and Sequoia Capital made suspicious payments to a politician's ...